Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
September 25 2017 - 9:23AM
Business Wire
Biogen (NASDAQ: BIIB) announced the appointment of Camille Lee
as Senior Vice President, Alzheimer’s Therapeutic Area, effective
today.
In her new role, Ms. Lee will be responsible for the design and
execution of commercial strategy for the company’s late-stage
Alzheimer’s disease assets and will work in partnership with
Biogen’s Research & Development function in overseeing Biogen’s
entire Alzheimer’s portfolio. She will be based in Cambridge,
Mass., and report directly to Chief Medical Officer Alfred
Sandrock, Jr., M.D., Ph.D.
Ms. Lee brings to Biogen more than 30 years of industry
experience. In her most recent role as Senior Vice President,
Diabetes & Obesity Marketing at Novo Nordisk, she led a team of
more than 500 professionals while overseeing the marketing of all
in-line and future brands as well as market access strategy. During
her time in this position, Novo Nordisk successfully launched two
brands that achieved leadership in their therapeutic areas.
“Camille’s experience in preparing markets and launching
products for highly prevalent diseases will serve us well as we
aspire to move toward commercializing our late-stage Alzheimer’s
disease candidates,” said Dr. Sandrock. “Her track record aligns
perfectly with our mission to deliver transformative therapies for
neurodegenerative diseases to patients who desperately need
them.”
Prior to taking a leadership role for Novo Nordisk’s diabetes
and obesity franchises, Ms. Lee worked across the organization. Her
tenure at Novo Nordisk included positions of increasing
responsibility in such functions as competitor intelligence,
product launch planning, and international marketing for multiple
endocrine products.
“Biogen’s R&D in Alzheimer’s is an inspiration, and I am
honored to be joining a company that has such an unwavering
commitment to the community,” said Ms. Lee. “I look forward to
working with the team as we aim to bring therapies to the market
that could make a difference to the thousands of patients and their
families that we serve.”
Ms. Lee holds a B.S. in Business Administration from California
State University, Long Beach, and an M.B.A. from Copenhagen
International Management Institute.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative
therapies for people living with serious neurological and
neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in
biotechnology, and today the company has the leading portfolio of
medicines to treat multiple sclerosis; has introduced the first and
only approved treatment for spinal muscular atrophy; and is at the
forefront of neurology research for conditions including
Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral
sclerosis. Biogen also manufactures and commercializes biosimilars
of advanced biologics. For more information, please visit
www.biogen.com. Follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to Biogen’s business activities, the
potential of Biogen’s commercial business and pipeline programs, ,
and the expected benefits from Ms. Lee’s appointment as our Senior
Vice President, Alzheimer’s Therapeutic Area. These forward-looking
statements may be accompanied by words such as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “except,” “forecast,” “intend,”
“may,” “plan,” “potential,” “possible,” “will,” and other words and
terms of similar meaning. Drug development and commercialization
involve a high degree of risk, and only a small number of research
and development programs result in commercialization of a product.
You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation: risks relating to
management and key personnel changes; failure to compete
effectively; difficulties in obtaining and maintaining adequate
coverage, pricing, and reimbursement for our products; potential
future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property, and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; uncertainty of success in
developing, licensing, or acquiring other product candidates or
additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in Biogen’s most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements are based on our current
beliefs and expectations and speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170925005775/en/
BiogenMEDIA CONTACT:Matt Fearer, +1
617-679-4462public.affairs@biogen.comorINVESTOR CONTACT:Mike Henke,
+1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Sep 2023 to Sep 2024